Evidence mapPaperPMID 42595817Full record

ArticleNature biotechnology2026

Proteome-wide identification of the druggable CRBN interactome.

Pius Galli, Shuhao Xiao, Yanxiang Meng, Alexander Hanzl, Alexandra M Bendel, Regina Baur, Jacob D Aguirre, Anna M Diaz-Rovira, Maximilian R Stammnitz, Georg Kempf and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Pius Galli *School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0009-0004-9280-9305
Shuhao Xiao *School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-7522-3626
Yanxiang MengSchool of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Alexander HanzlFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6004-2312
Alexandra M BendelSchool of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-5266-4675
Regina BaurSchool of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-5104-4888
Jacob D AguirreFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Anna M Diaz-RoviraSchool of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Maximilian R StammnitzCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0002-1704-9199
Georg KempfFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Lukas KaterFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Kenji ShimadaFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6670-3118
Ye WeiSchool of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-1965-2298
Andreas ScheckSchool of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-2123-6499
Dominique KleinFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Simone CavadiniFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Ben LehnerCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Guillaume DissFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.ORCID http://orcid.org/0000-0001-9153-4523
Bruno E CorreiaSchool of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-7377-8636
Nicolas H ThomäSchool of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. nicolas.thoma@epfl.ch.ORCID http://orcid.org/0000-0003-2685-906X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular glue degraders (MGDs), such as pomalidomide, induce degradation of non-native substrates by the cullin-RING E3 ligase 4 (CRL4) through its substrate receptor cereblon (CRBN). Here, to explore CRBN programmability, we tested whether reported CRBN-MGD substrates are part of a network of latent CRBN interactors, proteins capable of MGD-induced CRBN binding without detectable degradation. Leveraging a highly parallel protein complementation assay (GluePCA) to measure MGD-induced interaction between CRBN and zinc fingers, we identified ~210 zinc fingers bound to CRBN-pomalidomide, where top binders are already reported as degraded by dedicated MGDs. To map latent CRBN-MGD interactions proteome-wide and define the accessible CRBN interaction space, we combined artificial intelligence-derived protein surface queries (MaSIF-mimicry) with GluePCA. This pipeline identified 6 known and 43 novel CRBN-pomalidomide binders, including orthogonally validated hits. We find that these binders provide privileged starting points for MGD development. We expect this binding-focused workflow to be applicable to other MGD-E3 ligase systems, potentially extending the scope of this emerging drug class.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.